LEQEMBI®
(lecanemab) EISAI
HK Reg. No. HK-68289 (03 Jul, 2024) &
HK-68290 (03 Jul, 2024)
Composition:3
LEQEMBI® is an amyloid beta-directed antibody with the active ingredient lecanemab-irmb. It is administered as an intravenous infusion at a recommended dosage of 10 mg/kg that requires dilution.
Indication:3
LEQEMBI® is indicated for the treatment of Alzheimer’s disease in patients with mild cognitive impairment or mild dementia stage of disease.
References
1. TARGRETIN®. HIGHLIGHTS OF PRESCRIBING INFORMATION US 2015. https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021055s006lbl.pdf 2. AKEEGA™. Package Insert 2023. https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021055s006lbl.pdf 3. LEQEMBI®. HIGHLIGHTS OF PRESCRIBING INFORMATION US 2023. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761269Orig1s001lbl.pdf 4. LITFULO™. HIGHLIGHTS OF PRESCRIBING INFORMATION US 2023. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/215830s000lbl.pdf
